BackBiomarin Pharmaceutical - Registered Shares Overview

Biomarin Pharmaceutical - Registered Shares Other Current Liabilities

Track Biomarin Pharmaceutical - Registered Shares's other current liabilities ($800M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$798.87M

Peer trimmed avg / median

Loading

Biomarin Pharmaceutical - Registered Shares Other Current Liabilities History

Loading

Biomarin Pharmaceutical - Registered Shares vs. peers: Other Current Liabilities Comparison

Loading

Biomarin Pharmaceutical - Registered Shares Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Biomarin Pharmaceutical - Registered Shares (BMRN) FAQ

Biomarin Pharmaceutical - Registered Shares posts a other current liabilities of $800M as of September 2026. In the prior-year period, the figure was $0. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Biomarin Pharmaceutical - Registered Shares's other current liabilities was $0. The latest reading is $800M (period ending September 2026). Use the history and growth charts on this page for a longer lookback.

Other Current Liabilities is one piece of Biomarin Pharmaceutical - Registered Shares's financial statement story. At $800M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for BMRN's other current liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Biomarin Pharmaceutical - Registered Shares's other metric pages and overview cover the third.

Judging Biomarin Pharmaceutical - Registered Shares against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in other current liabilities easier to interpret. Start with $800M here, then scan peer and history charts to see if the gap is persistent.